BioTuesdays

BriaCell Therapeutics names two biopharma experts to its board

BriaCell

BriaCell Therapeutics (TSV-V:BCT; OTCQB:BCTXF) appointed Dr. Rebecca Taub and Vaughn Embro-Pantalony as directors, and current board members Dr. Saeid Babaei, Rahoul Sharan, and Martin Schmieg have resigned, effective immediately.

Mr. Embro-Pantalony is chairman of the board of Soricimed Biopharma and a director of Microbix Biosystems, where he also served as president and CEO from 2012 to 2017. Mr. Embro-Pantalony previously served as VP of finance, and CFO of Novopharm; VP of information technology, and chief information officer of Bayer; and VP of finance and administration of Bayer Healthcare.

Dr. Taub has been Madrigal Pharmaceuticals’ CMO and EVP of R&D, and a director since 2016. Previously, she served as SVP of R&D at VIA Pharmaceuticals; VP of research, metabolic diseases, at Hoffmann-La Roche; and in a variety of positions at Bristol-Myers Squibb and DuPont Pharmaceuticals.

BriaCell is developing immunotherapies for breast cancer. Its most advanced program is Bria-IMT, which achieved positive proof of concept in a Phase 2a study and is currently in an FDA approved combination study with Keytruda in advanced breast cancer patients.

BriaCell’s Bria-OTS is a collection of manufactured cell lines that express immune stimulating factors and a variety human leukocyte antigen (HLA) types. BriaCell’s BriaDX companion diagnostic identifies patients’ HLA type and which cell lines to use for immunotherapy, offering personalized treatment from pre-manufactured cell lines. Bria-OTS is expected to enter the clinic this year.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.